Trilaciclib to protect blood counts during ADC chemotherapy
Part of Cancer clinical trials.
This trial tests a drug called trilaciclib that may help protect your bone marrow from the side effects of a type of chemotherapy called an ADC drug. If you are scheduled to receive an ADC drug for your cancer, this study could help reduce the risk of low blood counts and the need for blood transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed cancer diagnosis that can be treated with a type of chemotherapy called an ADC drug (for example, regucitinib, gosatuzumab, luconasuzumab, or deconzumab).
- You are generally able to care for yourself (a score of 0 to 2 on the ECOG scale).
- You do not have a blockage in your stomach or intestines.
- You have good organ function (kidneys, liver, heart, and blood counts) as shown by recent blood tests.
- You have not received certain blood-boosting treatments (like G-CSF or blood transfusions) in the last 2 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding trilaciclib to standard chemotherapy before surgery for patients with newly diagnosed, high-grade osteosarcoma. Trilaciclib may help protect healthy cells during chemo treatment.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
This trial tests whether the drug trilaciclib can reduce low blood cell counts caused by chemotherapy in people with Ewing's sarcoma. If you qualify, you may receive a medication that could help protect your bone marrow during treatment.
This trial tests a drug called trilaciclib, given before chemotherapy, to see if it can protect your bone marrow and help prevent dangerous drops in blood cell counts. If you have head and neck cancer that has returned or spread and haven't had prior drug treatment, this might help you stay stronger during chemo.
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
This trial tests a drug called trilaciclib that may protect your bone marrow during chemotherapy for advanced bile duct or pancreatic cancer, potentially reducing side effects like low blood counts. It aims to make chemotherapy safer and more tolerable.
Hear when a new Tumor Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.